Apricus Biosciences Announces 2012 Year End Financial Results Conference Call
Conference Call/Webcast to be Held Monday, March 18, 2013 at 1:00 p.m. ET
SAN DIEGO, March 14, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced
today that it will hold a conference call to discuss its year end 2012
financial results and recent corporate highlights on Monday, March 18, 2013 at
1:00 p.m. ET. The Company expects to file its Form 10-K for the year ended
December 31, 2012 on Monday, March 18, 2013.
The call can be accessed in the U.S. by dialing 877-407-8031 and outside of
the U.S. by dialing 201-689-8031 and asking the conference operator for the
Apricus Bio Conference Call. The teleconference replay will be available for
one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by
dialing 201-612-7415. Replay passcode 410469 is required for playback. The
conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=170645. The webcast replay
will be available for three months.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (Nasdaq:APRI) is a pharmaceutical company that
develops and markets innovative treatments that help large patient populations
across numerous, large-market therapeutic classes including male and female
sexual health. The Company has one approved product, Vitaros®, for the
treatment of erectile dysfunction, which will be marketed in Canada by Abbott
Laboratories, and Femprox®, a product candidate, for the treatment of female
sexual arousal disorder, which successfully completed a nearly 400-subject
Phase III study in China.
For further information on Apricus Bio, visit http://www.apricusbio.com. You
can also receive information at http://twitter.com/apricusbio.
CONTACT: Apricus Bio Investor Relations:
David Pitts or Lourdes Catala
Press spacebar to pause and continue. Press esc to stop.